• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特罗非班检测与马拉维若短期病毒学应答的不吻合率。

Discordance rates between Trofile test and short-term virological response to maraviroc.

机构信息

Laboratory of Immunovirology, Biomedicine Institute of Seville, Service of Infectious Diseases, Virgen del Rocío University Hospital, Seville, Spain.

出版信息

Antiviral Res. 2011 Feb;89(2):182-5. doi: 10.1016/j.antiviral.2010.11.015. Epub 2010 Dec 4.

DOI:10.1016/j.antiviral.2010.11.015
PMID:21134404
Abstract

Enhanced sensitivity Trofile (ES-Trofile) is the most frequently used technique to assay HIV tropism. A clinical approach to predict CCR5-antagonists efficacy, based on the virological response to a short-term maraviroc exposure (Maraviroc Clinical Test, MCT), has been recently reported. We compared the results of ES-Trofile with MCT in 47 HIV-infected patients, and a global discordance around 15% was observed between the phenotypic method and the clinical approach. Discordance results were mainly found in patients with an ES-Trofile reported as dual/mixed. These provocative results might have important clinical implications and should be considered in order to accurately prescribe treatment with CCR5 antagonists.

摘要

增强敏感性分析(ES-Trofile)是目前最常用于检测 HIV 嗜性的技术。最近有报道称,基于短期马拉维若治疗的病毒学反应,采用临床方法预测 CCR5 拮抗剂的疗效。我们比较了 47 例 HIV 感染患者的 ES-Trofile 和 MCT 结果,表型方法和临床方法之间存在约 15%的整体差异。不一致的结果主要出现在报告为双重/混合的 ES-Trofile 患者中。这些有争议的结果可能具有重要的临床意义,应该加以考虑,以便准确地开具 CCR5 拮抗剂治疗。

相似文献

1
Discordance rates between Trofile test and short-term virological response to maraviroc.特罗非班检测与马拉维若短期病毒学应答的不吻合率。
Antiviral Res. 2011 Feb;89(2):182-5. doi: 10.1016/j.antiviral.2010.11.015. Epub 2010 Dec 4.
2
Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients.Trofile检测与HIV感染患者短期使用马拉维若治疗的病毒学反应之间的相关性。
J Antimicrob Chemother. 2009 Oct;64(4):845-9. doi: 10.1093/jac/dkp293. Epub 2009 Aug 11.
3
Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients.在初治的HIV-1感染患者中,短期使用马拉维若单药治疗的病毒学反应无法预测病毒嗜性。
J Antimicrob Chemother. 2014 Jul;69(7):1916-9. doi: 10.1093/jac/dku059. Epub 2014 Mar 12.
4
Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.深度测序分析马拉维若在短时间暴露于未感染患者体内时 HIV-1 准种的动态变化。
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.00390-18. Print 2018 Jun 1.
5
Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.马拉维若治疗非 R5 型 HIV-1 感染患者会导致选择具有有限总病毒设定值影响的极端 CXCR4 利用变异体。
J Antimicrob Chemother. 2013 Sep;68(9):2007-14. doi: 10.1093/jac/dkt153. Epub 2013 May 14.
6
Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients.马拉维若临床试验(MCT)作为一种替代工具,用于确定初治HIV感染患者中CCR5拮抗剂的处方。
Antiviral Res. 2015 Sep;121:94-6. doi: 10.1016/j.antiviral.2015.06.018. Epub 2015 Jun 26.
7
Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients.含马拉维若治疗方案在经大量治疗的 HIV-1 感染患者中的临床结局。
Int J Antimicrob Agents. 2016 Jan;47(1):84-90. doi: 10.1016/j.ijantimicag.2015.09.013. Epub 2015 Oct 25.
8
High prevalence of X4/DM-tropic variants in children and adolescents infected with HIV-1 by vertical transmission.高流行率的 X4/DM 嗜性变异体在儿童和青少年感染 HIV-1 的垂直传播。
Pediatr Infect Dis J. 2012 Oct;31(10):1048-52. doi: 10.1097/INF.0b013e3182684d8e.
9
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study.在HIV-1治疗失败患者中进行基因型或Trofile检测后含马拉维若方案的48周结果:OSCAR研究
New Microbiol. 2016 Jul;39(3):192-196.
10
Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment.接受马拉维若临床测试后的联合抗逆转录病毒疗法的患者并未出现免疫病毒学损伤。
Antiviral Res. 2012 Sep;95(3):207-11. doi: 10.1016/j.antiviral.2012.06.007. Epub 2012 Jun 27.

引用本文的文献

1
Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure.使用对短期马拉维若单药治疗暴露的病毒学反应验证HIV嗜性检测TROCAI
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6398-401. doi: 10.1128/AAC.01326-16. Print 2016 Oct.
2
Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients.短期使用马拉维若,一种用于决定对初治的HIV-1感染患者开具马拉维若处方的临床方法。
Drug Des Devel Ther. 2016 Jan 18;10:353-4. doi: 10.2147/DDDT.S100639. eCollection 2016.
3
A diagnostic HIV-1 tropism system based on sequence relatedness.
一种基于序列相关性的HIV-1嗜性诊断系统。
J Clin Microbiol. 2015 Feb;53(2):597-610. doi: 10.1128/JCM.02762-14. Epub 2014 Dec 10.
4
Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.短期马拉维若单药治疗的病毒学应答与基于标准和深度测序的基因型嗜性预测方法的相关性。
Antimicrob Agents Chemother. 2012 Mar;56(3):1202-7. doi: 10.1128/AAC.05857-11. Epub 2011 Dec 5.
5
Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.短期 CCR5 拮抗剂暴露后 HIV 感染患者的病毒学应答:具有病毒学应答的受试者的频率和相关因素。
Antimicrob Agents Chemother. 2011 Oct;55(10):4664-9. doi: 10.1128/AAC.00753-11. Epub 2011 Aug 1.